Login / Signup

Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?

Daniel Martin SimadibrataElvira LesmanaYeong Yeh Lee
Published in: Expert opinion on investigational drugs (2024)
PCAB has gained interest in recent years, with pharmacokinetics and pharmacodynamics properties surpassing PPI. Although recent data on PCABs, which comprised mainly of Vonoprazan, have shown promising results, more randomized controlled trials for other PCAB drugs are needed to elucidate and confirm the superiority of this drug class to PPI, the current first-line treatment of EE.
Keyphrases
  • protein protein
  • randomized controlled trial
  • helicobacter pylori
  • drug induced
  • electronic health record
  • big data
  • small molecule
  • machine learning
  • adverse drug